Octreotide, a long acting somatostatin analogue, was shown to prevent the stimulating effect of growth factors9 and inhibit noradrenaline-induced intracellular calcium uptake.'0 In addition, octreotide reduced left ventricular hypertrophy in patients with acromegaly."l-"3 In this study, three patients with primary hypertrophic cardiomyopathy were treated with octreotide. The plasma growth hormone concentrations were measured by radioimmunoassay (Orion Diagnostica, Espoo, Finland). The fasting baseline growth hormone concentrations of all cases were in the normal range (8-4 mIU/ml (3-0 ,ug/l) in case 1, 7.9 mIU/ml (2-82,g/l) in case 2, 5-1 mIU/ml (1 8 jug/l) in case 3 (normal range 0-14 mIU/ml (0-5,g/l) in adults) 
Hypertrophic cardiomyopathy has characteristic morphological features such as a hypertrophied and non-dilated left ventricle.' The myocardium typically shows disorganised cellular architecture, abnormally small intramural coronary arteries, and increased amounts of matrix or replacement fibrosis.2 Several mechanisms may contribute to the development of ventricular hypertrophy in hypertrophic cardiomyopathy. In earlier studies in patients with hypertrophic cardiomyopathy the response of the cardiovascular system to noradrenaline was increased, the sensitivity of the ,B adrenergic receptor was enhanced, and cardiac neuronal noradrenaline uptake was impaired. 34 An increase in calcium uptake and the calcium content of myocardium has also been reported. 5 The administration of nerve growth factor has been reported to increase catecholamine concentrations and cause hypertrophy and disarray in the myocardial fibres of dogs. 6 Toyozaki et al reported that insulin-like growth factor-I specific receptors are present in adult human cardiac myocytes. 7 Their data suggest that insulin-like growth factor-I receptors are related to the development of myocyte hypertrophy in hypertrophic cardiomyopathy. Sakata showed that the activities of transforming growth factor-I and angiotensin converting enzyme were increased in cardiomyopathic hamsters. 8 Octreotide, a long acting somatostatin analogue, was shown to prevent the stimulating effect of growth factors9 and inhibit noradrenaline-induced intracellular calcium uptake.'0 In addition, octreotide reduced left ventricular hypertrophy in patients with acromegaly."l-"3
In this study, three patients with primary hypertrophic cardiomyopathy were treated with octreotide. The plasma growth hormone concentrations were measured by radioimmunoassay (Orion Diagnostica, Espoo, Finland). The fasting baseline growth hormone concentrations of all cases were in the normal range (8-4 mIU/ml ,ug/l) in case 1, 7.9 mIU/ml (2-82,g/l) in case 2, 5-1 mIU/ml (1 8 jug/l) in case 3 (normal range 0-14 mIU/ml (0-5,g/l) in adults) Fractional shortening, mean velocity of circumferential fiber shortening, and ejection fraction were used in the assessment of left ventricular systolic performance. Peak flow velocities of the early and late diastolic fillings and their ratio were used in association with the transmitral flow sample to assess left ventricular diastolic performance.
Case 1 A 33 year old man had been diagnosed as having primary hypertrophic cardiomyopathy nine years before. He had been treated intermittently with propranolol or verapamil before octreotide was tried. His functional capacity was class II (New York Heart Association criteria (NYHA)). At physical examination, his blood pressure was 1 15/75 mm Hg. His heart rate was regular (72 beats/min). There was slight apical deviation to left lateral side and a double impulse at the apex. Left ventricular activity was 2 (+) and the fourth heart sound was heard. On the chest x ray the contour of the left ventricle was prominently curved. The At the end of the first week, blood pressure was 120/70 mm Hg and heart rate was 64 beats/min. P wave was 04 mV and T waves in leads V5 and V6 were diphasic.
At the end of four weeks treatment, the functional capacity was class I. The heart rate and systolic blood pressure were stable between 70 and 74 beats/min and 115 and 130 mm Hg respectively. The P wave was 0 3 mV. T waves were still inverted but not to the same extent as they were initially. The left ventricular mass was 35% smaller.
Case 2 Primary hypertrophic cardiomyopathy had been diagnosed in this 25 year old man six months before. He had been treated with mexiletine or amiodarone for his arrhythmias before octreotide was given. His functional capacity was class II. Blood pressure was 140/70 mm Hg and heart rate was 79 beats/min. There was double impulse at the apex. Left ventricular activity was 1(+). The fourth heart sound was heard. Electrocardiography showed sinus rhythm, left anterior hemiblock, ventricular hypertrophy (VlS+V5R = 4.6 mV), inverted T waves (in lead I, aVL), ST segment elevation (in lead V1-4), and giant T waves (in leads V1-4). This patient did not attend the follow up examination at three weeks. M mode variables before the treatment and during the first, the second, and the fourth weeks are shown in table 1. Table 2 shows systolic and diastolic performance indices before the treatment and during the fourth week.
Nodal premature systoles with a rate of [7] [8] beats/minute that had been observed on the previous electrocardiograms reappeared on the second treatment day. The inverted T waves became positive in lead I and diphasic in lead aVL on the second treatment day. At the end of the first week, there was no change in blood pressure and heart rate. T waves in lead aVL were inverted again. Amiodarone was added to the treatment on the tenth day.
At the end of the four weeks of treatment, his functional capacity improved from class II to class I. T waves became diphasic in lead I and inverted in lead aVL on electrocardiography. The left ventricular mass decreased by 19%.
Case 3
This 34 year old man had had primary hypertrophic cardiomyopathy for eight years and had been regularly treated with propranolol or verapamil before octreotide treatment. He was the brother of case one. Diazepam had been recently added to his treatment. His functional capacity was assessed as class III. Blood pressure was 80/40 mm Hg and heart rate 84 beats/min; the apex was slightly deviated to the left lateral side. There was double impulse at the apex and left ventricular activity was 2 (+). The fourth heart sound was also heard. On the chest x ray the contour of the left ventricle was prominently curved. Electrocardiography showed sinus rhythm, P pulmonale (0-6 mV in lead II), left ventricular hypertrophy (VlS+V5R = 6-4 mV), and inverted T waves (in leads I, aVL, V5, and V6). His M mode variables before treatment and during first, second, third, and fourth weeks are shown in table 1. Table 2 shows his systolic and diastolic performance indices before the treatment and during the fourth week.
At the end of the first week's treatment, blood pressure was 100/70 mm Hg and heart rate was 65 beats/min. The P wave was 04 mV and T waves in lead I, aVL, V5, and V6 were diphasic.
At the end of the four weeks' treatment, his functional capacity had improved from class III to class I. The heart rate and systolic blood pressure were stable between 70 and 75 beats/min and 100 and 110 mm Hg respectively. The P wave was 0-4 mV and T waves in lead I and V5 and V6 became positive. The left ventricular mass had decreased by 29%.
No side effects were seen in any of the three patients during octreotide treatment. Octreotide reduced left ventricular hypertrophy in patients with acromegaly."l-"3 Decreased interstitial oedema or myocyte regression were proposed as the mechanisms of regression." Primary hypertrophic cardiomyopathy and cardiac hypertrophy in acromegalic patients are different entities. However, it is possible that post-receptor events may be the common pathway in two diseases. After a six months octreotide treatment, Tokg6zoglu et al found that left ventricular mass decreased from 304 to 175 g in six patients with acromegaly."1 Similarly, Merola et al showed that left ventricular mass decreased by 18% in 11 patients with acromegaly.'2 In our study, after one month of octreotide treatment left ventricular mass decreased by 35%, 19%, and 29% in cases 1, 2, and 3 respectively (mean 24%). The differences between regression of left ventricular hypertrophy in patients with acromegaly and our patients may be attributed to the differences in sample numbers, doses of drug, and the duration of treatments. Moreover, these are two different diseases. We think that patients with primary hypertrophic cardiomyopathy are more sensitive to octreotide than acromegalic patients: there was a reduction of 24% in left ventricular mass within four weeks with a lower dose of octreotide in patients with primary hypertrophic cardiomyopathy compared with the reduction of 18% within six months with a higher dose of octreotide in patients with acromegaly.'2 Lim et However, left ventricular mass returned to the baseline value in all patients in six months despite the maintenance therapy with perindopril. We believe that until the prescription of depot forms of octreotide becomes possible, intermittent treatment will be needed in primary hypertrophic cardiomyopathy.
Our study had several limitations.The functional capacity could not be assessed by an exercise tolerance test. NYHA classification might not reflect actual functional capacity in hypertrophic cardiomypathy. In addition, endomyocardial biopsies could not be performed and myocardial concentrations of insulin-like growth factor I were not determined.
This study has been presented as a preliminary report. We believe that further larger studies are needed to asses the efficacy of octreoctide treatment in primary hypertrophic cardiomyopathy. In conclusion, the dramatic improvement seen after short term octreotide treatment in patients with primary hypertrophic cardiomyopathy seems promising.
